Picture loading failed.

Anti-TNFSF11 therapeutic antibody (Pre-made Denosumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-140-1mg 1mg 3090
GMP-Bios-ab-140-10mg 10mg 21890
GMP-Bios-ab-140-100mg 100mg 148000
GMP-Bios-ab-140-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-TNFSF11 therapeutic antibody (Pre-made Denosumab biosimilar,Whole mAb)
INN Name Denosumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2005
Year Recommended2006
CompaniesAmgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network
Conditions ApprovedBone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis
Conditions ActiveBreast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma
Conditions DiscontinuedMultiple myeloma
Development TechAbgenix XenoMouse